Synapse - Hematologic Malignancies Research

Results (3005)

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
Blood (2020)

Fulltext@MSK | Save

Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study

Meeting Abstract

Patel, K.; Ramchandren, R.; Maris, M.; Lesokhin, A. M.; von Keudell, G. R.; Cheson, B. D.; Zonder, J.; Seymour, E. K.; Catalano, T.; Lin, G. H. Y.; more...
Blood (2020)

Fulltext@MSK | Save

Targeted integration of a CAR at a novel genomic safe harbor directs potent therapeutic outcomes

Meeting Abstract

Odak, A.; Yuan, H.; Feucht, J.; Mansilla-Soto, J.; Eyquem, J.; Leslie, C.; Sadelain, M.
Blood (2020)

Fulltext@MSK | Save

Whole-genome sequencing reveals evidence of two biologically and clinically distinct entities: Progressive versus stable myeloma precursor disease

Meeting Abstract

Oben, B.; Froyen, G.; Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Abascal, F.; Leongamornlert, D. A.; Derkach, A.; Geerdens, E.; Diamond, B.; more...
Blood (2020)

Fulltext@MSK | Save

Transcriptional control of HP1a by the RNA binding proteins RBMX/L1 maintain chromatin state in myeloid leukemia

Meeting Abstract

Nguyen, D. T. T.; Prieto, C.; Liu, Z.; Wheat, J.; Perez, A.; Gourkanti, S.; Chou, T.; Barin, E.; Chow, A.; Taggart, J.; more...
Blood (2020)

Fulltext@MSK | Save

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save

CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma

Meeting Abstract

Madduri, D.; Berdeja, J. G.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; O'Donnell, E.; more...
Blood (2020)

Fulltext@MSK | Save

Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients

Meeting Abstract

Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
Blood (2020)

Fulltext@MSK | Save

The genomic complexity of multiple myeloma precursor disease can be predicted using copy number signatures on targeted sequencing and SNP array data

Meeting Abstract

Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; Landgren, O.; more...
Blood (2020)

Fulltext@MSK | Save

Evaluation of minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR Study

Meeting Abstract

Landgren, O.; Weisel, K.; Dachs, L. R.; Moreau, P.; Turgut, M.; Hajek, R.; Mollee, P.; Kim, J. S.; Zhang, J.; Go, N.; more...
Blood (2020)

Fulltext@MSK | Save